Difference between revisions of "Team:Manchester/Human Practices/Industries"

Line 293: Line 293:
 
   <div class="column fourfifth_size">
 
   <div class="column fourfifth_size">
 
     <div class="fours">
 
     <div class="fours">
     <p style="font-size:1.2em;">Lynn Shepherd, the director of Manchester Enterprise Centre and Martin Henry asked us about how we intended for our patch to eventually be cheaper than current breathalysers and electric devices. We said that in order to get a more accurate account for costs of a prototype we would need to do further research into it, but we are not at that stage in our experimentation yet.
+
     <p style="font-size:1.2em;">We had a meeting with Lynn Shepherd, the director of Manchester Enterprise Centre and Martin Henry, an Enterprise Academic Lecturer about our project. They intrigued us with their question on 'how our AlcoPatch (if the prototype is made) is going to be cheaper current breathalysers'. However, we could not give them an accurate estimate on the cost of our AlcoPatch as we are currently at the early stages of our <a href=" https://2016.igem.org/Team:Manchester/Proof" target="_blank">proof of concept</a>.
 
     <br /><br />
 
     <br /><br />
They also suggested we investigate whether what we were creating was novel or just a recalibration of existing designs. They suggested getting in contact with Curtis Dobson to ask if they could take a look at our models to understand the science behind them. They mentioned that we should be cautious about making too much of our product’s science available to the public as it could copied as we haven’t copyrighted anything yet. (<a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies" target="">meeting with Andrea Vero IP lawyer</a>)
+
They suggested we investigate whether our AlcoPatch is just a novel idea or a recalibration of existing designs. They also mentioned that we should be cautious about making too much of our product’s science available to the public as it could have patenting issues, leading to our (<a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies" target="">meeting with Andrea Vero</a>), an Intellectual Property Solicitor.
 
     <br /><br />
 
     <br /><br />
We also thought after the meeting that perhaps we could suggest that we could interchange chemicals with ethanol (in theory) like glucose (we did use glucose as <a href="" target="_blank">pilot experiment</a>). Which would mean that a patch could be designed to be easily interchangeable during manufacture to measure different chemicals in the sweat. Meaning a brand of patches which measure different chemicals could be created, which would standardise production to reduce production and design costs in the future. This model could become a business in itself and a cheap patch which can be made to measure different chemicals would be interest to many companies and corporations.
+
After this meeting , the question on cost led us to rethink our project idea. We had some interesting ideas, including using the mechanism behind AlcoPatch to detect other chemicals, such as glucose. This led us to conduct a <a href="https://2016.igem.org/Team:Manchester/Proof" target="_blank">pilot experiment</a> on glucose. The new patch could be designed to be easily interchangeable during manufacture to measure different chemicals in the sweat. This would allow an array of patches, which measures different chemicals, to be created. This would reduce production costs and would be of interest to many companies and corporations.
 
     </p>
 
     </p>
 
     </div>
 
     </div>
Line 314: Line 314:
 
   <div class="column fourfifth_size">
 
   <div class="column fourfifth_size">
 
     <div class="fours">
 
     <div class="fours">
     <p style="font-size:1.2em;">Two representatives of our team had a meeting with Professor Alan Dickinson (co director of BioProNET) and Dr Jo Flannelly ( network manager of BioProNET). They were very pleased with our project but also gave us an array of feedback for us to think about. Importantly they mentioned that ABTS is a carcinogenic substance. Therefore, the cell free mechanism couldn’t be marketed. Due to this, if we were to prolong the project  we would look for a substance which acts in the same way as ABTS but isn’t harmful to the consumers of this product (
+
     <p style="font-size:1.2em;">We had a meeting with Prof. Alan Dickinson (Co-director of BioProNET) and Dr. Jo Flannelly (network manager of BioProNET). They were very pleased with our project but also gave us an array of feedback for us to think about. Importantly they mentioned that ABTS is a carcinogenic substance. Therefore, the cell free mechanism could have marketing issues. As such, if we were to make the actual prototype, we would look for suitable alternatives for ABTS that does not pose a risk to the consumers (
 
<a href="https://2016.igem.org/Team:Manchester/Safety" target="_blank">Our Safety Page</a>).  
 
<a href="https://2016.igem.org/Team:Manchester/Safety" target="_blank">Our Safety Page</a>).  
 
   <br /><br />
 
   <br /><br />
They also made the point of financing the patch, is it really more cost effective than the breathalyzer and how much is the ptfe membrane we propose to use to enclose the reagents? Additionally, they suggested seeing an IP attorney in order to protect and patent our project. This was a new unexplored area of project that we hadn’t thought about yet. Therefore, we decided to contact an IP Attorney and get some more information about the legal process that could be involved with the production of our AlcoPatch. (
+
We also discussed about the financial aspect of the patch; Will it be more cost effective than the breathalyser? This question was also brought up during the meeting with <a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies" target="_blank">Lynn Shepherd</a>, the director of Manchester Enterprise Centre . Additionally, they suggested seeing an Intellectual Property (IP) attorney in order to protect and patent our project. This was a new unexplored area of project that we had not thought about before the meeting. Therefore, we decided to contact an IP Attorney and get some more information about the legal process that could be involved with the production of our AlcoPatch. (<a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies" target="_blank">Ward Hadaway and Venner Shipley</a>)
<a href="https://2016.igem.org/Team:Manchester/Human_Practices/Professional_Bodies" target="_blank">Ward Hadaway and Venner Shipley</a>)
+
 
     </p>
 
     </p>
 
     </div>
 
     </div>
Line 344: Line 343:
 
     <div class="fours">
 
     <div class="fours">
 
     <img src="https://static.igem.org/mediawiki/2016/a/a2/T--Manchester--hp_brightside.png" alt="picture with Carley" />
 
     <img src="https://static.igem.org/mediawiki/2016/a/a2/T--Manchester--hp_brightside.png" alt="picture with Carley" />
     <p style="font-size:1.2em;">Carley from Brightside Brewery suggested that this tool might not be useful to the vanilla student audience of drinkers as there is a culture of drinking where people might not necessarily be interested in monitoring their alcohol consumption, although experiments with a working prototype would show if there is interest for them. Perhaps, if the patch was marketed towards certain themes which students might like, then maybe there would be more uptake, themes like cartoons or films etc. make it fun.
+
     <p style="font-size:1.2em;"> We had an interesting meet up with Carley from Brightside Brewery, a family run local brewery. She suggested that our AlcoPatch might not be useful to the vanilla student audience of drinkers. This is due to a culture of drinking habits where people might not necessarily be interested in monitoring their alcohol consumption, although experiments with a working prototype has the potential to show different results.  
 
   <br /><br />
 
   <br /><br />
Carley suggested possible interest in the health sector, there could be people with undiagnosed health issues like violence which is triggered by consuming too much alcohol, a patch which monitors alcohol intake would help prevent violent situations perhaps. The NHS might use these patches as a part of education for people to know what the limit is so they best know how to drink responsibly. She mentioned  that the police could get involved with alcohol awareness schemes and this patch might be a way to improve that.
+
She also suggested possible interest in the health sector for people with undiagnosed health issues such as alcohol abuse. The National Health Sector (NHS, UK) might be able to use these patches as part of an educational tool to drink responsibly. She mentioned  that the police could get involved with alcohol awareness schemes and this patch might be a way to improve that.
 
   <br /><br />
 
   <br /><br />
We asked her whether she thought that breweries might find the patch useful and she said that they would have no use for them. Bars however, would have plenty of uses for them, but would they want to? It would not be in their interest to limit patron's consumption of alcohol. However, the patch could be used as a deterrent, for example difficult customers at bars who are drunk are told by bartenders that they cannot be served anymore. Quite often drunk people demand justification for being refused service, this patch could act as a back-up or justification tool for bartenders. This suggestion also conferred with what Dr Doherty (<a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries#ibcarb" target="_blank">Meeting with IB Carb</a>) suggested.  
+
However, she believed that breweries might not find the patch useful. Bars on the other hand, have the potential to be a market for AlcoPatch. Although It would not be in their interest to limit patron's consumption of alcohol, the patch could be used as a deterrence tool. This opnion also conferred with the suggestion from (<a href="https://2016.igem.org/Team:Manchester/Human_Practices/Industries#ibcarb" target="_blank">Dr Doherty</a>), Network Manager of IBCarb .  
 
     </p>
 
     </p>
 
     </div>
 
     </div>

Revision as of 16:31, 16 October 2016

Manchester iGEM 2016

Industries

H
U
M
A
N

P
R
A
C
T
  I
C
E
S

FREDsense

logo of FREDsense
picture for FREDsense

We had a conversation with Mr David Lloyd, Co-Founder and Chief Operating Officer of FREDsense Technologies. He provided valuable insights into the drinking habits and culture in Canada, which prompted us to have a discussion on the prospects of our AlcoPatch being marketed in Canada.

He highlighted that drink driving in Canada is a major issue and that methods of measuring blood alcohol levels can often have huge influences on legal cases. He added "any tool which can accurately read out someone’s blood ethanol concentration would be useful. However, these tests would need to be very quick as it would be impractical to have to wait for 10-30 minutes for an accurate reading". This led us to explore two different mechanisms with different response time and accuracy.

We also discussed concerns with regards to the acceptance of the public on the usage of genetically modified organisms (GMO). He mentioned that most members of the public are not aware of the low risk associated with GMOs. This issue has been raised on many occasions during our outreach events and suggests that there is an underlying lack of awareness on the safety of using GMOs.

IBCarb

logo of IBCarb
picture for IBCarb

We had a meeting with Dr.Doherty, the Network Manager of IBCarb. We pitched our project idea in order to get funding from IB Carb. She was very impressed with our project proposal and agreed to fund our project, enabling us to attend the Giant Jamboree. We also received many useful feedbacks from her, which were later used to improve certain aspects of our project. She also suggested that bouncers and bartenders would have great use of the AlcoPatch to measure the level of intoxication of consumers. This would help avoid the bartenders from selling alcohol to individuals who are very intoxicated.

NPRONET

logo of Npronet

We had a discussion with the networking manager of NPRONET (funded network in biotechnology and bioenergy), Ms Sarah Shephard. She was very forth coming of our project but advised us on getting our lab work done sooner due to the proof of concept element to our project. She also highlighted the issue of the AlcoPatch becoming a game amongst young adults, an issue which has been brought up by other individuals we have spoken to - Alcohol Academy and ESOF

Manchester Enterprise Centre

logo of Manchester Enterprise Centre

We had a meeting with Lynn Shepherd, the director of Manchester Enterprise Centre and Martin Henry, an Enterprise Academic Lecturer about our project. They intrigued us with their question on 'how our AlcoPatch (if the prototype is made) is going to be cheaper current breathalysers'. However, we could not give them an accurate estimate on the cost of our AlcoPatch as we are currently at the early stages of our proof of concept.

They suggested we investigate whether our AlcoPatch is just a novel idea or a recalibration of existing designs. They also mentioned that we should be cautious about making too much of our product’s science available to the public as it could have patenting issues, leading to our (meeting with Andrea Vero), an Intellectual Property Solicitor.

After this meeting , the question on cost led us to rethink our project idea. We had some interesting ideas, including using the mechanism behind AlcoPatch to detect other chemicals, such as glucose. This led us to conduct a pilot experiment on glucose. The new patch could be designed to be easily interchangeable during manufacture to measure different chemicals in the sweat. This would allow an array of patches, which measures different chemicals, to be created. This would reduce production costs and would be of interest to many companies and corporations.

BioProNET

logo of BioPronet

We had a meeting with Prof. Alan Dickinson (Co-director of BioProNET) and Dr. Jo Flannelly (network manager of BioProNET). They were very pleased with our project but also gave us an array of feedback for us to think about. Importantly they mentioned that ABTS is a carcinogenic substance. Therefore, the cell free mechanism could have marketing issues. As such, if we were to make the actual prototype, we would look for suitable alternatives for ABTS that does not pose a risk to the consumers ( Our Safety Page).

We also discussed about the financial aspect of the patch; Will it be more cost effective than the breathalyser? This question was also brought up during the meeting with Lynn Shepherd, the director of Manchester Enterprise Centre . Additionally, they suggested seeing an Intellectual Property (IP) attorney in order to protect and patent our project. This was a new unexplored area of project that we had not thought about before the meeting. Therefore, we decided to contact an IP Attorney and get some more information about the legal process that could be involved with the production of our AlcoPatch. (Ward Hadaway and Venner Shipley)

Brightside Brewery

logo of BioPronet
picture with Carley

We had an interesting meet up with Carley from Brightside Brewery, a family run local brewery. She suggested that our AlcoPatch might not be useful to the vanilla student audience of drinkers. This is due to a culture of drinking habits where people might not necessarily be interested in monitoring their alcohol consumption, although experiments with a working prototype has the potential to show different results.

She also suggested possible interest in the health sector for people with undiagnosed health issues such as alcohol abuse. The National Health Sector (NHS, UK) might be able to use these patches as part of an educational tool to drink responsibly. She mentioned that the police could get involved with alcohol awareness schemes and this patch might be a way to improve that.

However, she believed that breweries might not find the patch useful. Bars on the other hand, have the potential to be a market for AlcoPatch. Although It would not be in their interest to limit patron's consumption of alcohol, the patch could be used as a deterrence tool. This opnion also conferred with the suggestion from (Dr Doherty), Network Manager of IBCarb .